Profund Advisors LLC Purchases 18,489 Shares of ANI Pharmaceuticals, Inc. $ANIP

Profund Advisors LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 443.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 22,656 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,489 shares during the quarter. Profund Advisors LLC’s holdings in ANI Pharmaceuticals were worth $1,646,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in ANI Pharmaceuticals by 7.4% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 18,800 shares of the specialty pharmaceutical company’s stock valued at $1,366,000 after acquiring an additional 1,300 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of ANI Pharmaceuticals by 15.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,189 shares of the specialty pharmaceutical company’s stock worth $304,000 after acquiring an additional 571 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $436,000. Samalin Investment Counsel LLC raised its holdings in shares of ANI Pharmaceuticals by 18.0% in the third quarter. Samalin Investment Counsel LLC now owns 9,283 shares of the specialty pharmaceutical company’s stock valued at $674,000 after purchasing an additional 1,418 shares during the last quarter. Finally, Kendall Capital Management raised its holdings in shares of ANI Pharmaceuticals by 39.9% in the third quarter. Kendall Capital Management now owns 10,345 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 2,950 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ANIP shares. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective for the company. Finally, Guggenheim decreased their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $99.60.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $70.67 on Tuesday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock’s 50 day moving average price is $72.86 and its two-hundred day moving average price is $77.62. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 15.23, a P/E/G ratio of 2.31 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a 12-month low of $69.58 and a 12-month high of $95.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the company posted $1.80 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total transaction of $36,795.00. Following the completion of the transaction, the vice president directly owned 73,424 shares of the company’s stock, valued at $5,403,272.16. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $72.87, for a total transaction of $207,679.50. Following the completion of the transaction, the chief financial officer owned 166,143 shares in the company, valued at approximately $12,106,840.41. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,412 shares of company stock worth $2,220,970 in the last quarter. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.